Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study

Severe acute respiratory coronavirus-2 (SARS-CoV-2) still presents a public threat and puts extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment options are considered supportive. Tocilizumab as a treatment option has to date shown variable results. In...

Full description

Bibliographic Details
Main Authors: Ayman M. Al-Qaaneh, Fuad H. Al-Ghamdi, Sayed AbdulAzeez, J. Francis Borgio
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceutics
Subjects:
COVID-19 patient
tocilizumab
mortality
treatment
ICU admission
monoclonal antibody
Online Access:https://www.mdpi.com/1999-4923/14/3/624

Internet

https://www.mdpi.com/1999-4923/14/3/624

Similar Items